Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis

• Published in: Arthritis & rheumatology (Hoboken, N.J.) N.J.), 2016-08, Vol.68 (8), p.1914-1921
• Main Authors: van der Heijde, Désirée, Landewé, Robert B., Mease, Philip J., McInnes, Iain B., Conaghan, Philip G., Pricop, Luminita, Ligozio, Greg, Richards, Hanno B., Mpofu, Shephard
• Format: Article
• Language: English
• Subjects: Antibodies, Monoclonal - therapeutic use; Arthritis, Psoriatic - diagnostic imaging; Arthritis, Psoriatic - drug therapy; Arthritis, Psoriatic - pathology; Disease Progression; Double-Blind Method; Humans; Pharmaceutical industry; Psoriatic Arthritis; Tumor Necrosis Factor-alpha; Tumor necrosis factor-TNF
• ISSN: 2326-5191; 2326-5205
• DOI: 10.1002/art.39685

Objective To assess whether secukinumab treatment in patients with active psoriatic arthritis (PsA) is associated with sustained inhibition of radiographic progression. Methods In this phase III, double‐blind, placebo‐controlled study, 606 patients with PsA were randomized to receive intravenous (IV) secukinumab at a dose of 10 mg/kg (weeks 0, 2, 4) followed by subcutaneous secukinumab at a dose of 150 mg or 75 mg (the IV→150 mg and IV→75 mg groups, respectively) or placebo. Patients were stratified according to prior anti–tumor necrosis factor (anti‐TNF) exposure (71% were anti‐TNF naive). At week 16, placebo‐treated patients who had at least a 20% reduction in the tender and swollen joint counts (responders) continued to receive placebo until week 24; nonresponders were re‐randomized to receive secukinumab at a dose of 150 mg or 75 mg. The modified total Sharp/van der Heijde score (SHS) was determined at baseline, week 16 or 24, and week 52. Results In the overall population, radiographic progression was inhibited through 52 weeks; efficacy was demonstrated for both erosion and joint space narrowing scores and in patients who switched from placebo to secukinumab at week 24. Subgroup analyses showed that secukinumab reduced radiographic progression at week 24, regardless of previous anti‐TNF treatment. Among anti‐TNF–naive patients, the mean changes from baseline to week 24 in the modified total SHS were 0.05 in the pooled secukinumab group and 0.57 in the placebo group; among patients with an inadequate response or intolerance to anti‐TNF treatment, the mean changes were 0.16 and 0.58, respectively. Anti‐TNF–naive patients showed negligible progression through week 52. Inhibition of structural damage was observed through week 52 irrespective of concomitant methotrexate use. A high proportion of patients receiving secukinumab showed no progression (change in SHS of ≤ 0.5) from baseline to week 24 (82.3% of the IV→150 mg group and 92.3% of the IV→75 mg group) and from week 24 to week 52 (85.7% of the IV→150 mg group and 85.8% of the IV→75 mg group). Conclusion Secukinumab inhibited radiographic progression over 52 weeks of treatment in patients with active PsA.